1 Failure to induce remission at 10 weeks |
1 |
905 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.91 [0.81, 1.01] |
2 Failure to induce remission at 12 weeks |
2 |
1414 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.85 [0.78, 0.92] |
3 Failure to induce clinical response at 10 weeks |
1 |
905 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.85 [0.72, 1.00] |
4 Failure to induce clinical response at 12 weeks |
2 |
1414 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.76 [0.67, 0.86] |
5 Change in CDAI from baseline to 12 weeks |
1 |
507 |
Mean Difference (IV, Fixed, 95% CI) |
‐49.60 [‐67.35, ‐31.85] |
6 Adverse events up to week 12 |
2 |
1415 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.03 [0.98, 1.08] |
7 Withdrawal due to adverse event |
2 |
1415 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.86 [0.59, 1.26] |
8 Serious adverse events |
2 |
1414 |
Risk Ratio (M‐H, Random, 95% CI) |
0.76 [0.37, 1.56] |
9 Failure to induce remission at 10 weeks (post hoc subgroup analyses) |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
9.1 Patients with elevated CRP at baseline |
1 |
660 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.83 [0.73, 0.94] |
9.2 Concurrent use of immunosuppressants |
1 |
300 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.80 [0.67, 0.96] |
9.3 Previous use of anti‐TNF therapy |
1 |
358 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.85 [0.73, 0.98] |
10 Failure to induce remission at 12 weeks (post hoc subgroup analyses) |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
10.1 Patients with elevated CRP at baseline |
1 |
660 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.81 [0.71, 0.92] |
10.2 Concurrent use of immunosuppressants |
1 |
300 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.79 [0.65, 0.96] |
10.3 Previous use of anti‐TNF therapy |
1 |
358 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.85 [0.73, 0.98] |
11 Failure to induce clinical response at 10 weeks (post hoc subgroup analyses) |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
11.1 Patients with elevated CRP at baseline |
1 |
660 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.76 [0.63, 0.91] |
11.2 Concurrent use of immunosuppressants |
1 |
300 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.67 [0.51, 0.89] |
11.3 Previous use of anti‐TNF therapy |
1 |
358 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.68 [0.55, 0.84] |
12 Failure to induce clinical response at 12 weeks (post hoc subgroup analyses) |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
12.1 Patients with elevated CRP at baseline |
1 |
660 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.71 [0.58, 0.86] |
12.2 Concurrent use of immunosuppressants |
1 |
300 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.68 [0.51, 0.91] |
12.3 Previous use of anti‐TNF therapy |
1 |
358 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.67 [0.53, 0.83] |